Breaking
Markets
EUR/USD1.1768 0.06%GBP/USD1.3594 0.12%USD/JPY156.81 0.03%USD/CHF0.7778 0.09%AUD/USD0.7236 0.03%USD/CAD1.3680 0.16%USD/CNY6.8074 0.09%USD/INR94.57 0.08%USD/BRL4.9003 0.28%USD/ZAR16.43 0.06%USD/TRY45.38 0.04%Gold$4,676.10BTC$80,676 0.13%ETH$2,329 0.09%SOL$94.59 1.33%
Australia-Pacific

New Zealand's Pacific Edge aims to raise up to 24 million dollars more after US insurer loss

New Zealand-based cancer diagnostics company Pacific Edge is aiming to raise up to 24 million dollars in new capital after losing its largest US insurance contract. The company plans to enter the Asian market to diversify revenue. The stock fell 8% on the NZX after the announcement.

Biotechnology laboratory diagnostic testing equipment in clean room
Photo: Pavel Danilyuk / Pexels
RNZ Business57 min agoPEB NZD UNH

Pacific Edge develops the CxBladder urine-based bladder cancer detection tests. Its biggest US insurance partner, UnitedHealth, has removed the tests from its reimbursement list, an estimated loss of 18 million dollars in annual revenue.

The company plans to enter the Australia and Taiwan markets by the end of 2026, targeting 6 million dollars in annual revenue. Management said the capital raise will be open to institutional investors and high-net-worth individuals. North American headcount will be cut by 20%.

After the NZX drop, Pacific Edge's market capitalisation stands around 120 million dollars. Analysts expect near-term cash flow pressure to persist. The company is targeting positive EBITDA in early 2027. The New Zealand dollar held flat against the US dollar after the news.

EarningsRegulationPEBNZDUNHAustralia-PacificRNZ Business
This article is an AI-curated summary of the original story published by RNZ Business. The illustration is a stock photo by Pavel Danilyuk from Pexels and is not from the original story.

More from Australia-Pacific